Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Read More…
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-301-5157260
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees192
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Senseonics (NYSEAMERICAN:SENS) Frequently Asked Questions
What is Senseonics' stock symbol?
Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."
How were Senseonics' earnings last quarter?
Senseonics Holdings Inc (NYSEAMERICAN:SENS) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.05. The firm had revenue of $3.42 million for the quarter, compared to the consensus estimate of $4.05 million. View Senseonics' Earnings History.
When is Senseonics' next earnings date?
What price target have analysts set for SENS?
4 brokers have issued 12 month price targets for Senseonics' shares. Their predictions range from $6.00 to $6.00. On average, they anticipate Senseonics' stock price to reach $6.00 in the next year. This suggests a possible upside of 207.7% from the stock's current price. View Analyst Price Targets for Senseonics.
What is the consensus analysts' recommendation for Senseonics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Senseonics.
What are Wall Street analysts saying about Senseonics stock?
Here are some recent quotes from research analysts about Senseonics stock:
- 1. According to Zacks Investment Research, "Senseonics Holdings, Inc. is a medical technology company which focused on the design, development and commercialization of glucose monitoring systems. Senseonics Holdings, Inc. is based in Germantown, United States. " (5/11/2019)
- 2. BTIG Research analysts commented, "Senseonics’ reported Q2 sales relatively in line with our estimates and Street expectations. That put the focus squarely on observations from the first days of US launch. Early feedback points to doctors quickly becoming comfortable with the procedure and patients enjoying a long-lasting sensor. Additionally, revenue guidance for 2018 was increased by $1M because of additional confidence in both Europe and the US. We see this as a positive following FDA approval. In our view, the only factor hindering US patient and clinician appetite for Eversense is the timing of payor coverage, which we see as an issue of when, not if. We continue to model 2018 sales slightly above the guidance range. Although SENS shares have been weak since the company’s recent financing, we think shares may trade flat to slightly up Thursday with mgmt raising expectations a bit." (8/9/2018)
Has Senseonics been receiving favorable news coverage?
News headlines about SENS stock have trended very negative on Monday, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Senseonics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near term. View News Stories for Senseonics.
Who are some of Senseonics' key competitors?
Some companies that are related to Senseonics include Integral Diagnostics (IDX), Volpara Health Tech (VHT), Akumin (AKU), Palatin Technologies (PTN), Renalytix Ai (RENX), Profound Medical (PRN), MaxCyte (MXCT), Yourgene Health (YGEN), Oncimmune (ONC), Lexagene (LXG), Sernova (SVA), Oncosil Medical (OSL), SQI Diagnostics (SQD), GeneNews (GEN) and Deepmatter Group (DMTR).
What other stocks do shareholders of Senseonics own?
Who are Senseonics' key executives?
Senseonics' management team includes the folowing people:
- Dr. Timothy T. Goodnow, Pres, CEO & Director (Age 57)
- Dr. Mukul Jain, Chief Operating Officer (Age 46)
- Mr. Jon D. Isaacson, Chief Financial Officer
- Dr. Francine Ratner Kaufman, Chief Medical Officer
- Ms. Mirasol G. Panlilio, VP & Gen. Mang. of Global Commercial Operations (Age 54)
Who are Senseonics' major shareholders?
Senseonics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (10.03%), Janus Henderson Group PLC (1.00%), Raymond James & Associates (0.51%), Raymond James Financial Services Advisors Inc. (0.41%), Emerald Mutual Fund Advisers Trust (0.20%) and Daiwa Securities Group Inc. (0.07%). Company insiders that own Senseonics stock include Douglas A Roeder, Mukul Jain and Peter J Barris. View Institutional Ownership Trends for Senseonics.
Which major investors are selling Senseonics stock?
SENS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Raymond James Financial Services Advisors Inc., Gilder Gagnon Howe & Co. LLC, Emerald Mutual Fund Advisers Trust and Canton Hathaway LLC. View Insider Buying and Selling for Senseonics.
Which major investors are buying Senseonics stock?
SENS stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Raymond James & Associates, Marshall Wace North America L.P., Perkins Capital Management Inc., Mesirow Financial Investment Management Inc., Daiwa Securities Group Inc., Wealth & Pension Services Group Inc. and SG Americas Securities LLC. View Insider Buying and Selling for Senseonics.
How do I buy shares of Senseonics?
Shares of SENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Senseonics' stock price today?
One share of SENS stock can currently be purchased for approximately $1.95.
How big of a company is Senseonics?
What is Senseonics' official website?
How can I contact Senseonics?
Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The company can be reached via phone at +1-301-5157260.
MarketBeat Community Rating for Senseonics (NYSEAMERICAN SENS)
MarketBeat's community ratings are surveys of what our community members think about Senseonics and other stocks. Vote "Outperform" if you believe SENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
